{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:04:15Z","timestamp":1783742655532,"version":"3.55.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Breakpoint cluster region-Abelson (BCR-ABL) tyrosine kinase inhibitors (TKIs) demonstrate improved therapeutic efficacy in chronic myeloid leukemia (CML). However, drug\u2013drug interactions, nonadherence, and host-related factors may influence plasma concentrations. Therefore, therapeutic drug monitoring may be necessary for patients presenting inadequate treatment responses or adverse events. Herein, the authors aimed to develop a more sensitive and high-throughput method than those previously reported to simultaneously quantify 5 TKIs (imatinib, nilotinib, dasatinib, bosutinib, and ponatinib) and 2 active metabolites (<jats:italic toggle=\"yes\">N<\/jats:italic>-desmethyl imatinib and <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethyl ponatinib) using ultra-performance liquid chromatography coupled with tandem mass spectrometry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Plasma samples were prepared according to a solid-phase extraction protocol using an Oasis MCX \u00b5Elution plate. The assay fulfilled the requirements of the US Food and Drug Administration for assay validation, with a lower limit of quantification of 0.2 ng\/mL for dasatinib, 0.3 ng\/mL for <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethyl ponatinib, 0.5 ng\/mL for <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethyl imatinib, bosutinib, and ponatinib, and 2.5 ng\/mL for imatinib and nilotinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Within-batch and batch-to-batch precision at the lower limit of quantification and quality control levels were within 14.3% and 10.9%, respectively. Within-batch and batch-to-batch accuracies ranged from 15.5% to 13.0% and 5.70% to 7.03%, respectively. A positive electrospray ionization mode was used with a run time of 6.0 minutes. The assay applicability was verified by the successful measurement of 78 clinical samples from patients undergoing CML therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The method allows assessment of trough concentrations of TKIs and active metabolites in patients with CML, and hence can be used to assess blood samples in routine clinical settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000922","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:17:43Z","timestamp":1630531063000},"page":"419-429","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-2142","authenticated-orcid":false,"given":"Takahiro","family":"Sumimoto","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan;"},{"name":"Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University Hospital, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University Hospital, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy, and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-013-0041-1","article-title":"Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations","volume":"52","author":"Ince","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/17425255.4.2.137","article-title":"Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing","volume":"4","author":"Kacevska","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clinbiochem.2016.12.006","article-title":"The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study","volume":"50","author":"Obbergh","year":"2017","journal-title":"Clin Biochem."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukemia: comparing plasma levels of responders and non-responders","volume":"65","author":"Singh","year":"2006","journal-title":"Eur J Clin Pharmacol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure response analysis of nilotinib in patients with newly diagnosed Ph1 chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur J Clin Pharmacol."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jchromb.2007.01.019","article-title":"High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations","volume":"852","author":"Pursche","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchromb.2013.09.012","article-title":"High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study","volume":"939","author":"Kassem","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":"Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"27","author":"Titier","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2013.08.013","article-title":"A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry","volume":"937","author":"van Erp","year":"2013","journal-title":"J Schromatogr B Analyt Technol Biomed Life Sci."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"121928","DOI":"10.1016\/j.jchromb.2019.121928","article-title":"Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma","volume":"1137","author":"Mukai","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FTD.0000000000000357","article-title":"Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS\/MS","volume":"39","author":"Huynh","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","article-title":"High throughput routine determination of 17 tyrosine kinase inhibitors by LC\u2013MS\/MS","volume":"150","author":"Merienne","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jpba.2016.06.037","article-title":"Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology","volume":"25","author":"Rood","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchromb.2016.04.049","article-title":"Liquid chromatography\u2013tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma","volume":"1023-1024","author":"Sparidans","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s10147-018-1300-9","article-title":"Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study","volume":"23","author":"Mizuta","year":"2018","journal-title":"Int J Clin Oncol."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC\u2013MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma","volume":"877","author":"Franciaa","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab Dispos."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","article-title":"Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-017-3240-x","article-title":"Absorption, metabolism, and excretion of [14C] ponatinib after a single oral dose in humans","volume":"79","author":"Ye","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/chromsci\/bmt037","article-title":"LC\u2013MS-MS determination of imatinib and n-desmethyl imatinib in human plasma","volume":"52","author":"Zhang","year":"2014","journal-title":"J Chromatogr Sci."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:15:11Z","timestamp":1748970911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000922","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2021-03-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}